BioXcel Therapeutics – Consensus Indicates Potential 96.6% Upside

Broker Ratings

BioXcel Therapeutics found using ticker (BTAI) now have 10 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 185 and 68 with a mean TP of 112. Now with the previous closing price of 56.98 this would indicate that there is a potential upside of 96.6%. There is a 50 day moving average of 53.6 while the 200 day moving average is 48.33. The company has a market cap of $1,344m. Find out more information at: http://www.bioxceltherapeutics.com

BioXcel Therapeutics, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics has a collaboration with Merck KGaA; Nektar Therapeutics; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics is a subsidiary of BioXcel Corporation.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index